サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747777

ハイエンド・セルロミクスの世界市場

High End Cellomics

出版日
ページ情報
英文 212 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.42円
ハイエンド・セルロミクスの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 212 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ハイエンド・セルロミクスの世界市場は2030年までに70億米ドルに達する見込み

2024年に46億米ドルと推定されるハイエンド・セルロミクスの世界市場は、2024年から2030年にかけてCAGR 7.2%で成長し、2030年には70億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである機器は、CAGR6.2％を記録し、分析期間終了までに38億米ドルに達すると予測されます。試薬・消耗品セグメントの成長率は、分析期間中CAGR 8.3％と推定されます。

米国市場は12億米ドルと推定・予測、中国はCAGR 7.1％で成長予測

米国のハイエンド・セルロミクス市場は、2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.5％と6.2％と予測されています。欧州では、ドイツがCAGR約6.0%で成長すると予測されています。

世界のハイエンドセルロミクス市場- 主要動向と促進要因のまとめ

精密調査におけるハイエンドセロミクスの急速な台頭の原動力は？

ハイエンドセロミクスは、シングルセル解析、ライブセルイメージング、ハイコンテントスクリーニングにおいて前例のない能力を提供し、バイオメディカル研究の進化において極めて重要な分野として浮上しています。この分野は、高度なバイオイメージング、機械学習アルゴリズム、マイクロ流体技術を融合させ、細胞の挙動を超微粒子レベルで解読するものです。この分野を変革する中心的動向は、従来の集団ベースのアッセイから、細胞の不均一性を排除し、より正確で臨床に関連した洞察をもたらすシングルセルアプローチへの移行です。高スループットの顕微鏡検査とリアルタイムのAI対応解析の統合により、静的なスナップショットだけでなく、時間経過に伴う動的な細胞イベントの捕捉が可能になり、研究者はシグナル伝達カスケード、細胞周期の遷移、アポトーシス過程を高い忠実度で追跡できるようになりました。

マルチオミクス技術の並行的な急増は、セルロミクスの範囲をさらに広げました。個々の細胞からゲノム、トランスクリプトーム、プロテオーム、メタボローム・プロファイルを相関させる能力は、この分野を単なる視覚化の域を超えたものにしています。ハイエンドのセロミクス・プラットフォームは今や、腫瘍の微小環境、免疫細胞の機能、幹細胞の分化を単一細胞の解像度で理解するために不可欠なものとなっています。その結果、製薬会社は、特に腫瘍学、免疫療法、神経変性治療薬の開発において、ハイコンテンツ表現型スクリーニングのためのセロミクスツールに多額の投資を行っています。治療法の発見、毒性学的プロファイリング、細胞ベースのアッセイなど、その有用性は拡大しており、セルロミクスは次世代の精密医療の重要な柱として強化されつつあります。

イメージング、AI、流体工学の革新は、どのようにセロミクスツールキットを再構築しているのか？

ハイエンドのセロミクス市場の変革の中心には、技術の収束があります。刺激発光減弱法（STED）や構造化照明顕微鏡（SIM）など、蛍光顕微鏡や超解像顕微鏡の技術革新は、細胞内研究に必要な解像度とコントラストを大幅に向上させました。ライブセルイメージング機能と相まって、研究者は、最小限の光毒性で、細胞内相互作用や表現型の変化を経時的に観察できるようになりました。さらに、光学部品の小型化と自動プレートハンドリングシステムの統合により、1回の実験で数百、数千ウェルにわたるスケーラブルなイメージングワークフローが可能になりました。

人工知能は、ハイエンドのセロミクスにおいて、欠くことのできない増力剤として台頭してきました。機械学習アルゴリズムは、自動化された画像セグメンテーション、特徴抽出、予測的表現型決定にますます使用されるようになっています。膨大な細胞画像のライブラリーで訓練されたディープラーニング・プラットフォームは、現在、微妙な形態学的変化をリアルタイムで分類できるようになり、より正確な薬効試験に役立っています。さらに、AIによる異常検出と軌跡追跡は、セロミクスを静的な分析ツールから動的な意思決定システムへと高めています。マイクロ流体システムの搭載も、マイクロスケールでの正確な細胞選別、環境制御、試薬の送達を容易にすることで、セロミクス・プラットフォームの分析能力を強化しています。

ハイエンド・セルオミクスは、どのような用途で利用されているのか？

ハイエンド・セルロミクスの応用分野は、特に創薬、毒性学、免疫学、再生医療の分野で急速に多様化しています。医薬品の研究開発では、バイオマーカーだけに頼ることなく、細胞やサブセルレベルで薬物反応を評価することができるため、化合物のスクリーニングにおいて、セロミクスは重要な役割を果たしています。これは、薬剤開発パイプラインの早い段階でオフターゲット効果を特定し、投与方法を最適化するために不可欠です。がん研究は、セロミクスが、異種腫瘍サンプルのプロファイリング、免疫細胞浸潤の評価、治療抵抗性パターンの予測など、科学者の方法を変革している主要な領域として際立っています。

免疫学では、セロミクスは従来の方法では不可能であったT細胞、B細胞、抗原提示細胞の機能プロファイリングを可能にします。このことは、ワクチン開発や免疫腫瘍学において、微調整された免疫細胞のモニタリングが、設計や有効性評価の指針となることに大きな意味を持っています。同様に幹細胞生物学も、分化経路や系統の追跡、エピジェネティクスの変化を経時的にモニターできるようになり、ハイエンドのセロミクスの恩恵を受けています。臨床研究所やCROもまた、患者層別化やバイオマーカー検証のためにセロミクスツールを導入しており、細胞集団を大規模に解析する能力は、個別化された治療計画や疾患進行モニタリングをサポートしています。このように前臨床とトランスレーショナルな環境での利用が拡大していることは、現代のバイオサイエンスにおけるハイエンドセロミクスの範囲が広がっていることを裏付けています。

ハイエンドセロミクス市場の成長はいくつかの要因によって牽引される...

成長を後押ししているのは、主に製薬・バイオテクノロジー業界におけるハイコンテンツ分析プラットフォームの高度化と需要の増加です。これらの促進要因の中で重要なのは、予測毒性学と表現型スクリーニング・システムに対するニーズの高まりであり、セルロミクスは従来の手法に比べて優れたスループットと精度を提供します。また、免疫療法や細胞療法のパイプラインの拡大により、免疫反応を単一細胞レベルで理解するための高解像度でダイナミックなイメージングツールが必要とされています。さらに、マルチプレックスアッセイやハイスループットスクリーニングキャンペーンの普及により、イメージング、データ解析、自動化を組み合わせた統合ソリューションへの需要が高まっています。

学術研究センターやトランスレーショナルリサーチセンターも、複雑な疾病メカニズムの解明や治療標的の検証能力を高めるため、ハイエンドのセロミクスプラットフォームに投資しています。患者由来のオルガノイドや3D細胞培養システムの重要性が高まるにつれ、非単分子層構造のイメージングや解析が可能なプラットフォームに対する市場の関心がさらに高まっています。さらに、ライフサイエンス研究、特に腫瘍学、神経科学、希少疾患などの分野では、政府や民間からの資金援助が先進的なセロミクスシステムの普及を後押ししています。最後に、光学ハードウェア、計算生物学、アッセイ小型化の絶え間ない進歩により、ハイエンドのセロミクスツールは、よりアクセスしやすく、スケーラブルで、より幅広い科学的探究に適用できるようになっています。

セグメント

製品タイプ（装置、試薬＆消耗品、ソフトウェア＆サービス）、用途（創薬、がん研究、神経科学、幹細胞研究＆再生医療、個別化医療、その他の用途）、技術（顕微鏡、フローサイトメトリー、シングルセルゲノミクス、質量分析、次世代シーケンサー、その他の技術）、最終用途（製薬＆バイオテクノロジー企業、病院＆診断ラボ、契約研究機関、その他の最終用途）

調査対象企業の例（全34件）

  • 10x Genomics
  • Agilent Technologies
  • BD（Becton, Dickinson）
  • Bio-Rad Laboratories
  • Bio-Techne
  • Bruker Corporation
  • Cellenion
  • Cellomics Technology
  • CYTENA GmbH
  • Danaher Corporation
  • Dolomite Bio
  • GE Healthcare
  • Illumina Inc.
  • Luminex Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • NanoString Technologies
  • PerkinElmer Inc.
  • Sphere Fluidics
  • Thermo Fisher Scientific

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35174

Global High End Cellomics Market to Reach US$7.0 Billion by 2030

The global market for High End Cellomics estimated at US$4.6 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 7.1% CAGR

The High End Cellomics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global High-End Cellomics Market - Key Trends & Drivers Summarized

What Is Driving the Rapid Emergence of High-End Cellomics in Precision Research?

High-end cellomics is emerging as a pivotal discipline in the evolving landscape of biomedical research, offering unprecedented capabilities in single-cell analysis, live-cell imaging, and high-content screening. This field represents the fusion of advanced bioimaging, machine learning algorithms, and microfluidic technologies to decode cellular behavior at an ultra-granular level. A core trend transforming the sector is the shift from traditional population-based assays to single-cell approaches that eliminate cellular heterogeneity and yield more precise, clinically relevant insights. The integration of high-throughput microscopy with real-time AI-enabled analysis has made it possible to capture not just static snapshots but dynamic cellular events over time, allowing researchers to track signaling cascades, cell cycle transitions, and apoptotic processes with high fidelity.

A parallel surge in multi-omics technologies has further enhanced the scope of cellomics. The capacity to correlate genomic, transcriptomic, proteomic, and metabolomic profiles from individual cells has propelled the field beyond mere visualization. High-end cellomics platforms are now essential for understanding tumor microenvironments, immune cell function, and stem cell differentiation at single-cell resolution. As a result, pharmaceutical companies are investing heavily in cellomics tools for high-content phenotypic screening, especially in oncology, immunotherapy, and neurodegenerative drug development. The expanding utility across therapeutic discovery, toxicological profiling, and cell-based assays is reinforcing cellomics as a critical pillar in the next generation of precision medicine.

How Are Innovations in Imaging, AI, and Fluidics Reshaping the Cellomics Toolkit?

Technological convergence lies at the heart of the high-end cellomics market transformation. Innovations in fluorescence and super-resolution microscopy, such as stimulated emission depletion (STED) and structured illumination microscopy (SIM), have substantially improved the resolution and contrast needed for subcellular studies. Coupled with live-cell imaging capabilities, researchers can now observe intracellular interactions and phenotypic changes over time with minimal phototoxicity. This is further supported by the miniaturization of optical components and the integration of automated plate handling systems, enabling scalable imaging workflows across hundreds or thousands of wells in a single experiment.

Artificial intelligence has emerged as an indispensable force multiplier in high-end cellomics. Machine learning algorithms are increasingly used for automated image segmentation, feature extraction, and predictive phenotyping. Deep learning platforms trained on vast libraries of cellular images now allow real-time classification of subtle morphological changes, aiding in more precise drug efficacy testing. Moreover, AI-driven anomaly detection and trajectory tracking have elevated cellomics from a static analysis tool to a dynamic decision-making system. The inclusion of microfluidic systems has also bolstered the analytical capabilities of cellomics platforms by facilitating precise cell sorting, environmental control, and reagent delivery at the microscale, which is particularly vital for longitudinal studies on rare cell populations.

Where Is High-End Cellomics Gaining Ground Across Applications?

The applications of high-end cellomics are rapidly diversifying, particularly within the realms of drug discovery, toxicology, immunology, and regenerative medicine. In pharmaceutical R&D, cellomics plays a key role in compound screening, allowing researchers to assess drug responses at the cellular and subcellular levels without relying on biomarkers alone. This is critical for identifying off-target effects and optimizing dosage regimes early in the drug development pipeline. Cancer research stands out as a dominant domain where cellomics is transforming how scientists profile heterogeneous tumor samples, evaluate immune cell infiltration, and predict therapeutic resistance patterns.

In immunology, cellomics enables functional profiling of T cells, B cells, and antigen-presenting cells in ways not possible through traditional methods. This has profound implications for vaccine development and immune-oncology, where fine-tuned immune cell monitoring can guide both design and efficacy evaluation. Similarly, stem cell biology is benefiting from high-end cellomics by enabling researchers to monitor differentiation pathways, lineage tracing, and epigenetic shifts over time. Clinical laboratories and CROs are also deploying cellomics tools for patient stratification and biomarker validation, where the ability to analyze cell populations at scale supports personalized treatment planning and disease progression monitoring. This growing use across preclinical and translational settings underscores the broadening reach of high-end cellomics in modern biosciences.

The Growth in the High-End Cellomics Market Is Driven by Several Factors…

It is primarily the increasing sophistication and demand for high-content analysis platforms in pharmaceutical and biotechnology industries that is fueling growth. Key among these drivers is the rising need for predictive toxicology and phenotypic screening systems, where cellomics offers superior throughput and accuracy compared to conventional methods. The expansion of immunotherapy and cell therapy pipelines has also necessitated high-resolution, dynamic imaging tools for understanding immune responses at the single-cell level. Furthermore, the proliferation of multiplexed assays and high-throughput screening campaigns is driving demand for integrated solutions that combine imaging, data analytics, and automation.

Academic and translational research centers are also investing in high-end cellomics platforms to enhance their ability to dissect complex disease mechanisms and validate therapeutic targets. The growing importance of patient-derived organoids and 3D cell culture systems has further bolstered market interest in platforms capable of imaging and analyzing non-monolayer structures. Additionally, government and private funding in life sciences research, particularly in areas like oncology, neuroscience, and rare diseases, is supporting the widespread adoption of advanced cellomics systems. Finally, the continuous advancements in optical hardware, computational biology, and assay miniaturization are making high-end cellomics tools more accessible, scalable, and applicable across a wider range of scientific inquiries.

SCOPE OF STUDY:

The report analyzes the High End Cellomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Application (Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine, Other Applications); Technology (Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing, Other Technologies); End-Use (Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 10x Genomics
  • Agilent Technologies
  • BD (Becton, Dickinson)
  • Bio-Rad Laboratories
  • Bio-Techne
  • Bruker Corporation
  • Cellenion
  • Cellomics Technology
  • CYTENA GmbH
  • Danaher Corporation
  • Dolomite Bio
  • GE Healthcare
  • Illumina Inc.
  • Luminex Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • NanoString Technologies
  • PerkinElmer Inc.
  • Sphere Fluidics
  • Thermo Fisher Scientific

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • High End Cellomics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Content Screening in Drug Discovery Drives Adoption of Advanced Cellomics Platforms
    • Growth in Personalized Medicine and Precision Oncology Spurs Investment in Cell-Based Analytical Technologies
    • Expansion of Cell-Based Assays in Toxicology and Target Validation Fuels Market for High-End Imaging and Quantification Systems
    • Integration of AI and Deep Learning Algorithms Enhances Cellomics Image Analysis Accuracy and Throughput
    • Increased Adoption of 3D Cell Culture and Organoids Boosts Demand for Sophisticated, High-Resolution Cell Imaging Systems
    • Automation and Miniaturization Trends in High-Throughput Screening Support Deployment of Fully Integrated Cellomics Workstations
    • Rising R&D Expenditure by Pharmaceutical and Biotechnology Companies Drives Large-Scale Investment in Cellomics Infrastructure
    • Growing Applications in Stem Cell Research and Regenerative Medicine Expand the Market for Functional Cell Phenotyping Tools
    • Technological Advancements in Fluorescence and Live-Cell Imaging Elevate Performance of Next-Generation Cellomics Platforms
    • Surge in Use of Cellomics in Immuno-Oncology and CAR-T Therapy Research Strengthens Market Expansion
    • Increased Focus on Multi-Parameter Analysis Drives Demand for Multiplexed and High-Content Cellomics Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World High End Cellomics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for High End Cellomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for High End Cellomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Microscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Single-Cell Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Single-Cell Genomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Hospitals & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Stem Cell Research & Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Stem Cell Research & Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • JAPAN
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • CHINA
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • EUROPE
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for High End Cellomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for High End Cellomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • FRANCE
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • GERMANY
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030

IV. COMPETITION